ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2022
First-in-Humans Brain PET Imaging of the GluN2B-Containing
Open access · bronzeAbstract read
In one paragraph
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 20 citations in OpenAlex.
- A Study of 3-Substituted 7-Methoxy-2,3,4,5-tetrahydro-1Molecules (Basel, Switzerland) · 2026Article
- Trajectories of late-life depression: insights from molecular imaging.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Review
- The neuroendocrine regulation of hepatic cytochrome P450 by N-methyl-D-aspartate receptors in the paraventricular and arcuate nuclei of the hypothalamus.Drug metabolism and disposition: the biological fate of chemicals · 2025Article
- Oral Abstracts.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2023Article
- Special Issue "In Vivo Nuclear Molecular Imaging in Drug Development and Pharmacological Research".Pharmaceuticals (Basel, Switzerland) · 2023Article
- Translational molecular imaging and drug development in Parkinson's disease.Molecular neurodegeneration · 2023Review
- Recent Developments in Carbon-11 Chemistry and Applications for First-In-Human PET Studies.Molecules (Basel, Switzerland) · 2023Review
- Evaluation of (Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Biodistribution and dosimetry of the GluN2B-specific NMDA receptor PET radioligand (R)-[EJNMMI research · 2022Article
- Development and Validation of [Pharmaceuticals (Basel, Switzerland) · 2022Article
- Comparison of three novel radiotracers for GluN2B-containing NMDA receptors in non-human primates:Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2022Article
- Characterization in nonhuman primates of (R)-[European journal of nuclear medicine and molecular imaging · 2022Article
- NRM 2021 Abstract Booklet.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 6 institutions in 2 countries.
Lucas RischkaDepartment of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.
Chrysoula VrakaDivision of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.
Verena PichlerDivision of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.
Sazan RasulDivision of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.
Lukas NicsDivision of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.
Gregor GryglewskiDepartment of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.
Patricia HandschuhDepartment of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.
Matej MurgašDepartment of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.
Godber M GodbersenDepartment of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.
Leo R SilberbauerDepartment of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.
Jakob UnterholznerDepartment of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.
Christoph WotawaDepartment of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.
Achi HaiderCentre for Radiopharmaceutical Sciences ETH-PSI-USZ, Institute of Pharmaceutical Sciences ETH, Zurich, Switzerland.
Hazem AhmedCentre for Radiopharmaceutical Sciences ETH-PSI-USZ, Institute of Pharmaceutical Sciences ETH, Zurich, Switzerland.
Roger SchibliCentre for Radiopharmaceutical Sciences ETH-PSI-USZ, Institute of Pharmaceutical Sciences ETH, Zurich, Switzerland.
Thomas MindtDivision of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.
Markus MitterhauserDivision of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.
Wolfgang WadsakDivision of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.
Andreas HahnDepartment of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria.
Rupert LanzenbergerDepartment of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria; simon.ametamey@pharma.ethz.ch marcus.hacker@meduniwien.ac.at rupert.lanzenberger@meduniwien.ac.at.
Marcus HackerDivision of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria; simon.ametamey@pharma.ethz.ch marcus.hacker@meduniwien.ac.at rupert.lanzenberger@meduniwien.ac.at.
Simon M AmetameyCentre for Radiopharmaceutical Sciences ETH-PSI-USZ, Institute of Pharmaceutical Sciences ETH, Zurich, Switzerland; simon.ametamey@pharma.ethz.ch marcus.hacker@meduniwien.ac.at rupert.lanzenberger@meduniwien.ac.at.
Medical University of Vienna · ATETH Zurich · CHLudwig Boltzmann Institute Applied Diagnostics · ATCenter For Biomarker Research In Medicine · ATCentre d'Imagerie BioMedicale · CHUniversity of Vienna · AT
Funding
Austrian Science Fund FWF DOC 33
Abstract
The
Indexed as
Alzheimer DiseaseReceptors, N-Methyl-D-AspartateAspartic AcidBenzazepinesBrainHumansMalePositron-Emission TomographyReproducibility of ResultsTomography, X-Ray Computed(11)C-Me-NB1Aspartic AcidBenzazepinesReceptors, N-Methyl-D-AspartateGluN2B subunitsglutamateneurodegenerative diseaseN-methyl-d-aspartate (NMDA)PET
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.